Position in SYRE
as of Jun 30, 2026
· filed Aug 5, 2026
Position Value
$50,376,435
+$19,438,305 QoQ
Shares Held
567,430
-7.5% QoQ
Ownership
0.644%
of shares outstanding
% of Portfolio
1.19%
of 13F equity value
Holder Rank
#36
of 266 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority
Sole 76%
Shared 0%
None 24%
Common Shares in SYRE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026EMERALD ADVISERS, LLC holds $600,984,884 across 23 Biotechnology names. SYRE ranks #5 (8.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TVTX |
Travere Therapeutics, Inc.
|
1,600,886 | $90,946,333 | |
| 2 | CORT |
Corcept Therapeutics Inc
|
748,325 | $65,066,858 | |
| 3 | COGT |
Cogent Biosciences, Inc.
|
1,603,319 | $62,048,445 | |
| 4 | MIRM |
Mirum Pharmaceuticals, Inc.
|
468,295 | $54,823,295 | |
| 5 | SYRE |
Spyre Therapeutics, Inc.
This page
|
567,430 | $50,376,435 | |
| 6 | CYTK |
Cytokinetics Inc
|
457,956 | $39,013,271 | |
| 7 | MANE |
Veradermics, Inc
|
288,370 | $35,452,207 | |
| 8 | PVLA |
Palvella Therapeutics, Inc.
|
229,486 | $35,070,050 |
All Filings in SYRE
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $50,376,435 | 567,430 | Shares | Sole | 2026-08-05 | |
| 2026-03-31 | $30,938,130 | 613,365 | Shares | Sole | 2026-05-04 | |
| 2025-12-31 | $20,838,930 | 636,109 | Shares | Sole | 2026-02-09 | |
| 2025-09-30 | $9,196,413 | 548,712 | Shares | Sole | 2025-10-30 | |
| 2025-06-30 | $8,470,969 | 565,863 | Shares | Sole | 2025-08-04 | |
| 2025-03-31 | $8,839,188 | 547,827 | Shares | Sole | 2025-05-01 | |
| 2024-12-31 | $12,729,294 | 546,791 | Shares | Sole | 2025-02-11 | |
| 2024-09-30 | $8,604,454 | 292,569 | Shares | Sole | 2024-10-29 | |
| No filing history on record for this holder in this stock. | ||||||